Targeting acute kidney injury with LSALT peptide
LSALT Peptide (Metabloktm)
LSALT peptide is the company’s lead drug candidate for the prevention of Acute Kidney Injury (AKI) and other common inflammation injuries in the kidneys, liver and lungs.
Arch is focused on a path to drug approval for LSALT peptide to prevent AKI and organ inflammation in common injury and disease applications where there are no effective drugs or treatments available in the market today.

Click to WATCH LSALT peptide At work
Video data behind Arch lead scientists publication in Cell shows the real-time effects of LSALT peptide when used to prevent inflammation in pre-clinical models of AKI, similar to the inflammation found in CS-AKI – click to watch the videos below.
The company is sponsoring an ongoing Phase II international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI). Drug approval for treating this type of inflammation related kidney injury may enable off-label use for other indications such as lung or liver inflammation injury, other AKI indications and septic shock.
A NEW PEPTIDE DRUG CANDIDATE AND DPEP1 INHIBITOR
Arch believes that LSALT peptide has the potential to deliver a major breakthrough in the treatment of common injuries and diseases where organ inflammation affects millions of patients globally every year.
In August 2019, a scientific team led by Arch scientists Dr. Donna Senger and Dr. Stephen Robbins published a paper in the journal Cell describing a novel mechanism of action for organ inflammation.
In the paper, the enzyme dipeptidase-1 (DPEP1) was identified as a major neutrophil (white blood cell) adhesion receptor on the lung, liver and kidney endothelium – additionally, DPEP1 was shown to be the target of LSALT peptide – identifying a target for neutrophil-driven inflammatory diseases of the lungs, differing from typical anti-inflammatory drugs by targeting this novel adhesion receptor rather than targeting individual cytokines.
In 2024 Arch scientists were published in the journal BMJ Open, this time with the Proof of Concept study results for the company’s 2021-2022 Phase II trial. The data from that trial provided the first-ever evidence validating Dipeptidase-1 (DPEP1) as a mediator of organ inflammation and therapeutic target in humans. In addition, the article included crucial evidence that LSALT peptide was well tolerated with no safety issues related to the drug.
BMJ Open – March 2024
Publication of proof of concept study of LSALT peptide
Phase II trial results provided first-ever evidence validating Dipeptidase-1 (DPEP1) as a mediator of organ inflammation and therapeutic target in humans.
Arch is developing LSALT peptide to treat acute kidney injury (AKI) and organ damage caused by inflammation
The current LSALT peptide Phase II cardiac surgery-associated acute kidney injury (CS-AKI) trial began dosing patients in March 2024. The trial began with five active hospital sites in Turkey, and has since added three hospital sites in Canada (two pending activation). The complete study is planned to include up to 240 patients in Turkey, Canada and the United States.
- November 2024, announcement of dosing of the first patient dosed at the University of Calgary, Cumming School of Medicine, the first Canadian site to join and activate in the trial.
- April 2024, announcement of St Michael’s Hospital and Toronto General Hospital (UHN) joining the trial.
- March 2024, dosing of first patient in Turkey marking the commencement of the Phase II CS-AKI trial.
- March 2024, announcement of first Canadian site to join the trial, beginning with the University of Calgary, Cumming School of Medicine.
- March 2024, publication of previous Phase II trial results providing further scientific rationale to advance LSALT peptide to prevent leukocyte recruitment and organ inflammation for other indications.
- June2023, successfully obtained the U.S. FDA’s permission to proceed with the Phase II trial to prevent CS-AKI.